SCHEMBL25588160

SCHEMBL25588160

CCN(C[C@@]1(C)CCc2cc(-c3nnn(C)n3)c(C)nc2N1)C(=O)[C@@H](C)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 13/20 0.45
▸ HCRTR1 O43613 5/20 0.33
▸ CETP P11597 1/20 0.32
▸ RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588147 1.00 MC4R (0.45) MC4RHCRTR1CETPRORC
SCHEMBL25587588 0.87 MC4R (0.42) MC4RHCRTR1RORC
SCHEMBL25587195 0.79 MC4R (0.45) MC4RHCRTR1
SCHEMBL24940768 0.78 MC4R (0.70) MC4R
SCHEMBL31139136 0.78 MC4R (0.70) MC4R
SCHEMBL24940011 0.78 MC4R (0.70) MC4R
SCHEMBL25587236 0.77 MC4R (0.45) MC4RHCRTR1RORC
SCHEMBL25587223 0.77 MC4R (0.45) MC4RHCRTR1RORC
SCHEMBL25587311 0.75 MC4R (0.43) MC4RRORC
SCHEMBL25587277 0.75 MC4R (0.43) MC4RRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 — — US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR MC4R, MC2R, NPY4R MC4R 1/4885HCRTR1 30/4885CETP 4242/4885
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof MC4R, MC3R, MC5R MC4R 1/4885HCRTR1 51/4885CETP 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback